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Summary The effects of tumour cells (Colon 26) on the development and response of new blood vessels to
different vasoconstrictors (platelet activating factor; PAF, endothelin-1, angiotensin II, adrenalin and 5-
hydroxytryptamine) have been investigated. Sponge implants in mice were used to host tumour cells while
washout of '33Xe was employed to assess local blood flow in the implanted sponges.
By 14 days after implantation the response of vessels in tumour-bearing implants to the various vasocon-
strictors generally was decreased compared to that obtained in control sponge implants or adjacent normal
skin. Thus at this time point the tl/2 for '33Xe washout from control sponges treated with adrenalin (0.5pg)
was 30 ± 4 min whereas in tumour-bearing sponges it was 5 ± 1 min.
This decreased sensitivity in tumour vessels was probably not due to a complete lack of contractile elements
since actin was demonstrated by immunohistochemistry around blood vessels in both types of implant.
The results of the present study have shown that the pharmacological responses of blood vessels in a
growing tumour, Colon 26, differed from the responses of vessels of a similar age in non-neoplastic tissue.
These results appear to suggest that the different angiogenic stimuli released from tumour tissue may markedly
influence pharmacological reactivity of newly formed blood vessels.
Tumour angiogenesis, the formation of capillary vessels
induced by neoplastic cells with eventual development of a
functional microcirculatory network within the growing
mass, is a process analogous to the formation of capillary
vessels in granulation tissue during wound repair (Warren,
1979). Morphological abnormalities in vessels in either situa-
tion have frequently been reported (Schoelfl, 1963; Warren,
1979; Jain 1988; Vaupel et al., 1989). However, compared to
other angiogenic stimuli, tumours induce a very intense and
persistent response (Folkman & Klagsbrun, 1987) so that
more severe abnormalities may be observed in tumour
vessels; this tendency is accentuated in rapidly growing neop-
lasms (Vaupel et al., 1989). Pharmacological as well as
anatomical abnormalities have been documented in tumour
blood vessels, though the situation is far from clear-cut.
Thus, experimental studies have suggested either increased
(Young et al., 1979; Tveit et al., 1981), similar (Mattsson et
al., 1982) or decreased (Wickersham et al., 1977) sensitivity
to vasoactive stimuli in the tumour vascular bed compared to
normal tissue. These differences have been attributed to the
transplantation area of the tumour, the type of tumour and
the different techniques used for measuring blood flow
(Suzuki et al., 1984). The washout of locally injected radioac-
tive '33Xe (Peterson, 1979) has been shown to be a reliable
index of tumour blood flow when applied to relatively small,
superficially located cancers (Kallman et al., 1972). This tech-
nique has also been used for examining the influence of
vasoactive drugs on local blood flow in tumours and normal
subcutaneous tissue (Mattsson et al., 1980; 1982). Previously
we have used washout of '33Xe to show a temporal progres-
sion in blood flow and functional characteristics of newly
formed blood vessels within subcutaneous granulation tissue
in sponge implants in rats and in mice (Andrade et al., 1987;
Andrade et al., 1991).
Sponge implants provide a physically well defined in vivo
compartment particularly useful for investigating the changes
that accompany ingrowth of vascularised connective tissue.
The sponge has also been used as a framework to host
different tumour cell lines in rodents (Thiede et al., 1988;
Mahadevan & Hart, 1991) which permits the analysis of
newly formed tumour blood vessels. In this paper, using our
sponge implant system to host Colon 26 tumours and
washout of '33Xe to assess local blood flow in the implanted
sponges, we have studied the angiogenic effects of an
adenocarcinoma on neovascularisation of sponge implants in




Adult male Balb/c mice weighing 20-28 g were used for all
experiments.
Sponge implants
Polyether-polyurethane sponge discs, 4 mm height x 8 mm
diameter (Vitafoam Ltd., Manchester, UK) were used as the
matrix to host tumour cells and to monitor for angiogenesis.
One end of a polythene tubing 1.2 cm long x 1.2 mm internal
diameter (Portex Ltd., Hythe, Kent, UK) was secured to the
centre of each disc with two 5/0 silk sutures (Ethicon Ltd.,
UK) so that the tube was perpendicular to the disc face. The
sponge discs with cannula attached were soaked overnight in
70% v/v ethanol and sterilised by boiling in distilled water
for 15 min.
Implantation ofsponges
Discs were implanted using aseptic techniques in mice anaes-
thetised by intramuscular injection of Hypnorm and Hyp-
novel (0.5 ml kg-' of each). The dorsal hair was shaved and
the skin wiped with 70% ethanol. A 1 cm mid-line incision
was made and through it one subcutaneous pocket was
prepared by blunt dissection. A sterilised sponge implant was
then inserted in the pocket, its cannula being pushed through
a small incision which had been made previously on the top
of the pocket. The base of the cannula was sutured to the
skin. The cannula was then plugged with a smaller piece of
sealed polythene tubing. The mid-line incision was closed by
2-3 silk sutures and the animals were housed singly with free
access to food and water.
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Establishment oftumour-bearing implants
Colon 26 cells (Tsuro et al., 1983) were cultured in Dulbec-
co's modification of Eagle's essential medium supplemented
with 10% foetal bovine serum and 1% L-glutamine. Once
confluent the monolayer was harvested by incubation for
2 min with trypsin/EDTA (0.025% and 0.02 w/v respec-
tively). The dislodged cells were centrifuged for 10min and
adjusted to the appropriate concentration in saline; 50 LI of
the cell suspension (1 x 106 cells) were injected into the
sponges 2 days after their implantation. This procedure
yielded a tumour take of 100% producing progressive grow-
ths which were visible around 10 and 12 days after cell
injection (i.e. 12-14 days after sponge implantation).
Histological examination ofimplants
At fixed times, mice were anaesthetised then killed by cervical
dislocation and the sponge implants dissected free from sub-
cutaneous tissue. The implants were fixed in formalin (10%
w/v in isotonic saline) and transverse sections were cut (5gm)
from half way through the sponge's thickness. Identification
ofa-actin was achieved using streptavidin-peroxidase staining
with a swine antibody to rabbit o-actin (1:500) which cross-
reacts with murine a-actin. This contractile protein was dem-
onstrated in cells within the walls of the blood vessels. Some
sections were stained with haematoxylin and eosin (H&E).
Bloodflow measurement
To determine of local blood flow in control and tumour-
bearing implants, the mice were anaesthetised with
Hypnorm/Hypnovel as before and a 10IlI bolus of 133Xe,
containing 103 counts per s, was injected into the sponge
implant via the cannula which was quickly plugged to pre-
vent evaporation of the gas. The washout of the radioactive
tracer was followed by external detection with a collimated
gamma-scintillation detector (sodium iodide-thalium
activated crystal; 1 inch by 1 inch) positioned 1 cm directly
above the site of the injection. The radioactivity was
accumulated for 40 s over 6 min after injection and the 40 s
counts printed automatically on an SR7 scaler ratemeter
(Nuclear Enterprises Ltd., London, UK). The rate of
washout of 133Xe was expressed in terms ofits half-time (tl/2;
time taken for the radioactivity to fall to 50% of its original
value).
Assessment ofpharmacological reactivity ofnewlyformed
blood vessels in control and tumour-bearing implants
In any single implant, the untreated tl/2 value was measured
following the injection of saline alone. Then 40 min later the
tl/2 value was established following the administration of a
specific vasoconstrictor. Up to three successive '3Xe washout
assays, with 45 min intervals, were possible in one implant
per day. At the end of the experimental session, the animal
was kept warm until it had recovered fully from anaesthesia.
Preliminary experiments showed that untreated tl/2 values
were constant from day to day after day 8 (i.e. 6 days after
cell injection) in the tumour-bearing implants and from day
10 for control implants; successive assays on the same day
also gave constant tl/2 values.
Responses of the vessels to vasoconstrictors PAF (0.1, 0.5,
1 and 2pg), endothelin-1 (0.125 and 1.25 ng), angiotensin II
(0.05 and 0.5pg), adrenalin (0.05, 0.5 and 5yg) and 5-
hydroxytryptamine (5-HT) (0.1 and 1 .tg) or sterile saline
were measured. Injections of the vasoactive agents were made
into the sponges (50 1AI) and skin (10ft), immediately before
the "'Xe solution was given.
Chemicals
Xenon injection, "'Xe (1OmCi in 3 ml) was obtained from
Amersham International, UK. Platelet activating factor
(PAF; 1-0- alkyl - 2 - acetyl - sn-glycero-3-phosphorycholine),
angiotensin II, adrenalin, 5-hydroxytrytamine (5-HT) and
monoclonal anti a-smoooth muscle actin clone 1A4 all came
from Sigma Chemical Co. Ltd.; endothelin-I porcine was
from Peninsula Laboratories, Inc., (Belmont, Calif, USA);
Hypnorm (0.315 mgml-' fentanyl citrate and 10 mgml-'
fluanisone acetate) was purchased from Janssen Phar-
maceuticals, Oxford, UK; and Hypnovel (5 mg ml-' of
midazolam hydrochloride) was bought from Roche Phar-
maceuticals, Welwyn Garden City, UK.
Statistical analysis
Results are given as mean(± s.e.m.) values from n animals.
Comparison between groups was made with Student's t-test
for unpaired data and a P value less than 0.05 was con-
sidered significant.
Results
The angiogenic effect of tumour cells was assessed in the
subcutaneous sponge implants by the progressive fall in "'Xe
tl/2, i.e. progressive increase in local blood flow. In the
control sponges, the "'Xe decreased from 26 ± 4 min at day
4 to reach tl/2 of normal skin values 5 ± 1 min by 14 days
postimplantation. In the presence of tumour cells, this pro-
cess was accelerated and normal skin values were attained
before 10 days (i.e. 8 days after tumour cell injection) with a
very marked effect at day 7 postimplantation (tumour tl/2
= 7 + 1; control tl/2 = 15 ± 2 min). At this stage (7 days) in
histological sections of the sponges, using the routine H&E
staining, capillary-like structures were evident in tumour
bearing implants but not in the control implants. However,
at 14 days postimplantation blood vessels were evident in
both types of implants. Histological examination of the sec-
tions stained for a-actin immunoreactivity showed positive
reaction in control and tumour-bearing implants with no
obvious difference between the two groups (Figure 1).
Responses ofthe vasculature in control and tumour-bearing
animals
The effects of a number of vasoconstrictors were measured
firstly in normal skin. These results (Table I) showed that the
doses used caused marked increases in tl/2 values as a conse-
quence of vasoconstriction.
The vasoconstrictors were then assessed for their effect on
the vasculature in the implants. In the first set of such
experiments, the vasomotor response to endothelin-1 was
measured at day 10 postimplantation in both types of im-
plant (i.e. 8 days after tumour cell injection in tumour-
bearing implants). The initial washout rate of "'Xe in control
implants (7.8 ± 1 min; n = 4) was not different from that in
tumour-bearing implants (6 ± 1 min; n = 4) under these con-
ditions. After a bolus injection of endothelin-l (1.25 ng),
blood flow in both implants decreased, i.e. tl/2 increased
markedly, in both control and tumour-bearing implants
(Figure 2). However, at the later stage of 14 days postimp-
lantation, the tl/2 values in untreated implants of either type
were again equal (5.1 ± 0.7 min, control; 6 ± 1.6 min,
tumour-bearing implant; n = 4), and the response to
endothelin-l (1.25 ng) in control implants was marked by a
substantial increase in tl/2 value (29 ± 3 min) but the tumour
response was now substantially less than that seen at day 10,
or that manifest by 14 day control sponge, with a tl/2 of
11 ± 1 min. (Figure 2).
Because of this divergence between control and tumour
vessel response, all subsequent tests of vasoreactivity were
made in implants at 14 days. Figure 3 shows the blood flow
in control implants and the blood flow in tumour-bearing
implants in response to four different vasoconstrictors. Over
a range of doses for each vasoconstrictor there was a res-
ponse as shown by the increase in t1/2 in the control
implants. By contrast, the vessels in the tumour-bearing
implants did not respond to PAF (0.1; 1 and 2pg) or to low
doses of endothelin-l, angiotensin II and adrenalin.TUMOUR ANGIOGENESIS 823
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Figure 1 Photomicrograph of control sponge implants a, (day 14 postimplantation) and Colon 26-bearing implants b, (day 14
postimplantation, i.e. 12 days after tumour cell injection) immunostained for a-smooth muscle actin (Streptavidin-peroxidase
staining). Positive reaction is localised in the walls of vessels (arrows). Bars = 20ILm.
Table I Effects of local injected vasoconstrictors on the washout of
'33Xe from skin
tJ/2 (min) of'33Xe washout
Untreated skin (10) 5± 1.8
PAF 0.1 iLg (4) 6±1
1tlg (7) 12±la
Endothelin-l 0.125 ng (5) 14±2a
1.25 ng (8) 22±la
Angiotensin II 0.05Ag (4) 10±0.3a
0.5 Lg(5) l5±la
5-HT 0.1 lg (6) 11 1.5a
Ilg (7) 15 2a
Adrenalin 0.05 ytg (3) 9± la
0.5ig (3) 19±3a
The values in the Table are the mean s.e.m. from the number of
animals shown in parentheses. ap<0.05, different from untreated skin
values.
Significant responses were obtained at higher doses of the
mediators but markedly less than in the control implants.
Responses to 5-HT were generally similar in both control
and tumour-bearing implants in that no significant
differences in tl/2 values were recorded between the two
groups at any of the doses used (Figure 3c).
Discussion
Our results have confirmed the angiogenic effects of an
adenocarcinoma cell line growing in subcutaneously
implanted sponge discs (Mahadevan & Hart, 1991). These
implants provide a well-defined, initially avascular compart-
ment for the growth of tumour cells. Neovascularisation of
the implant was assessed by '33Xe washout and has been
correlated with histological evidence of vessel growth (And-
rade et al., 1987); the progressive fall in tl/2 reflected
development of blood vessels in the implant. In the present
experiments using this technique early changes in blood flow
could be detected even before visible growth of the tumour
mass was apparent.
The combination of sponge implant and '33Xe washout
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Figure 2 Responses ofColon 26 blood vessels to endothelin-1 during tumour development. Response ofvessels to endothelin-I was
measured by the rate ofI33Xe washout at day 10 and 14 postimplantation in control a, and tumour-bearing implants b. The tl/2 values
from untreatedimplants aredemonstrated (emptycolumns). Thevasoconstrictoreffectoftheagentdid notchangefromday 10 today 14
in the control implants but was lost in the tumour-bearing implants from day 10 to day 14. The values shown represent mean ± s.e.m.































Figure 3 Vasoconstrictor effects of angiotensin II, adrenalin, 5-HT and PAF in tumour-bearing implants (-)and control implants
(0) measured at day 14 after implantation. The values to the left of the break represent '33Xe washout from untreated implants.
Although the untreated tl/2 values were identical for control and tumour-bearing implants, the vasoconstrictor effects (increased
tl/2) were consistently lower (angiotensin II, endothelin-l) or absent (PAF) in tumour-bearing implants. Note that with 5-HT, both
sets of implants showed identical responses. The values shown represent mean ± s.e.m. from 4-8 animals at each dose. *P<0.05,
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perties of newly formed blood vessels and to compare the
response of vessels in neoplastic tissue with vessels in
granulation tissue. Abnormal angioarchitecture has been
demonstrated in granulation tissue; such abnormalities are
comparable to those found in capillary sprouts in tumours
(Warren, 1979). We have also observed that, in the absence
of tumour cells, newly formed blood vessels infiltrating the
sponge matrix exhibited features such as dilatation, tortuosity
and saccular structure (Andrade unpublished results). All
these features are apparent in tumour blood vessels (Jain,
1988; Vaupel et al., 1989).
The method allows non-destructive repeated measurements
of blood flow in the same animal over the period of neovas-
cularisation of the implants; thus changes occurring during
the development of normal or tumour vasculature may be
followed in the same animals. Consequently we were able to
demonstrate clearly that there was a change in vaso-reactivity
to endothelin-1 between 10 and 14 days in the tumour-
bearing implants. A similar progressive loss in the capacity to
react to vasoactive agents by blood vessels in experimental
mammary tumours as the tumours enlarged was reported by
Wickersham et al. (1977). A possible explanation for the
progressive loss of reactivity in tumour, but not control,
implants could be that, unlike the vessels of inflammatory
granulation tissue, tumour vessels are characterised by a
steady progression to necrosis without any intervening stable
maturation phase (Suzuki et al., 1984). Another contributing
factor could be that during neoplastic growth some of the
preexisting host vessels incorporated in the tumour mass
disintegrate, are obstructed or are compressed (Vaupel et al.,
1989).
At the 14 day time point decreased sensitivity in the
tumour neovasculature relative to the age-matched control
neovasculature was the predominant response to most of the
vasoconstrictors used in our experiments. However one
vasoconstrictor, 5-HT, elicited very similar responses in all of
the three vascular beds examined (normal skin, control
implants and tumour implants). A normal vasoconstrictor
response to 5-HT also has been reported in subcutaneously
implanted Meth-A tumours (Stucker et al., 1991). Several
studies have suggested that arteries and arterioles are resis-
tant to neoplastic invasion (Intaglietta et al., 1977; Warren,
1979). Possibly intact innervation and contractile elements
may remain in normal blood vessels incorporated in the
invading tumour mass, thus maintaining the ability to res-
pond to serotoninergic agonists. A weak response was
obtained to angiotensin II and adrenalin in neoplastic tissue
only after administration of a dose 10-100 fold greater than
that which evoked a response in the control neovasculature.
Suzuki et al. (1984) observed that newly growing tumour
vessels did not react to topically administered angiotensin II.
The vessels supplying tumours have been reported to be
relatively unreactive to locally applied drugs which act on
smooth muscle (Hirst et al., 1991). This lack of response
might reflect a lack of structural strength, with tumour
vessels having little smooth muscle and a poorly organised
adventitia (Can et al., 1984). Interestingly then our
immunohistochemical studies failed to show any marked
differences in actin content between control and tumour-
bearing implants (Figure 1). Though this assessment is, of
necessity, crude it could suggest that decreased sensitivity in
Colon 26 tissue is not due to a lack ofcontractile elements in
tumour blood vessels. Perhaps other factors could contribute
to the differences observed in our system. For example,
tumour vascular endothelium possesses immature cell con-
tacts within the endothelial lining of the vessel wall (Warren,
1979; Jain, 1988). We have shown that the pharmacological
responses of blood vessels in a growing tumour, Colon 26,
differed considerably from the responses of vessels of a
similar age which were not associated with neoplastic tissue.
We have observed similar pharmacological differences
between normal and B16 melanoma neovasculature (unpub-
lished observations) suggesting this response is not a unique
property of the Colon 26 tumours. These findings suggest
that the nature of the angiogenic stimulus influences the
pharmacological behaviour of newly formed blood vessels.
The experimental system described here may be of some
utility in the search for therapeutically useful, phar-
macological differences between normal and tumour vas-
culature.
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